News
Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...
National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...
Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...
Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...
Insider Monkey on MSN2d
Hims (HIMS) Jumps 8.6% as Firm Still Open to Work With NovoWe recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...
8h
Zacks Investment Research on MSNHims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA-based health and wellness ...
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results